Clinical trial
Treatment of Hepatitis C Virus Infection With Direct-acting Antiviral Drugs in Patients With Hemoglobinopathies
NCT03149289 is registered in ClinicalTrials.gov with Società Italiana Talassemie ed Emoglobinopatie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Treatment of Hepatitis C Virus Infection With Direct-acting Antiviral Drugs in Patients With Hemoglobinopathies
- Lead sponsor
- Società Italiana Talassemie ed Emoglobinopatie
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 1, 2015
- Completion date
- February 1, 2017
- Enrollment
- 168 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.